Hospitech Cancer Care Innovations Successfully Completes Clinical Trial for EEMC: A Breakthrough in Real-Time Gastrointestinal Cancer Detection

🔬 Clinical Trial Validates Electrical Endoscopic Mass Characterizer (EEMC) for GI Cancer Detection

Electrical Endoscopic Mass Characterizer (EEMC), developed by Hospitech Cancer Care Innovations, is a next-generation diagnostic platform designed to enhance the accuracy and speed of gastrointestinal (GI) cancer detection during endoscopy. The device has now successfully completed a clinical trial, validating its use for real-time, intraoperative assessment of malignant GI lesions.

This milestone brings the EEMC closer to market readiness, promising a game-changing advancement in endoscopic oncology diagnostics.

➡️ Read the study in Digestive Diseases and Sciences (Springer Nature)

📊 Clinical Performance of the EEMC Device

The recent clinical study enrolled 52 patients undergoing upper GI endoscopic procedures. The EEMC was used to evaluate suspicious lesions in real time using electrical impedance spectroscopy (EIS), a technique proven effective in differentiating tissue types.

➡️ Learn more about Electrical Impedance Spectroscopy in medicine (NIH)

Key trial outcomes:

• ✅ Sensitivity: 94.7%

• ✅ Specificity: 93.9%

• ✅ Accuracy: 94.2%

• ✅ Diagnosis Time: Under 10 seconds

• ✅ Workflow Impact: Fully compatible with standard endoscopy practices

⚙ How the Electrical Endoscopic Mass Characterizer (EEMC) Works

The EEMC integrates seamlessly with modified biopsy forceps. It uses electrical impedance spectroscopy (EIS) to measure Z1kHz and impedance phase slope (IPS) via a work/sense electrode and counter electrode. These indicators allow real-time classification of lesions as “normal” or “excision-required.”

➡️ Explore EIS technology at ScienceDirect

🏥 Clinical Applications of EEMC

Designed for:

• Gastroenterology clinics

• Endoscopic surgery units

• Cancer screening centers

Targets:

• Gastric adenocarcinoma

• Esophageal cancer

• Pre-cancerous dysplasia

• Intestinal metaplasia

➡️ For cancer prevalence data, visit World Cancer Research Fund

🌍 What’s Next for the Electrical Endoscopic Mass Characterizer (EEMC)?

Hospitech is moving toward CE certification and global market entry by Q4 2025. We are actively forming partnerships with healthcare professionals and institutions seeking innovative endoscopic diagnostic solutions.

📣 Contact Us

Hospitech Cancer Care Innovations is committed to revolutionizing cancer diagnostics through real-time, minimally invasive technologies.

🔗 Visit us: www.hospital-tech.com
📧 Email: info@hospital-tech.com
📞 Phone: +968 93 99 34 01